Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

作者：Sobh M; Michallet M^*; Gahrton G; Iacobelli S; van Biezen A; Schoenland S; Petersen E; Schaap N; Bonifazi F; Volin L; Meijer E; Niederwieser D; El Cheikh J; Tabrizi R; Fegeux N; Finke J; Bunjes D; Cornelissen J; Einsele H; Bruno B; Potter M; Fanin R; Mohty M; Garderet L; Kroeger N

来源：Leukemia, 2016, 30(10): 2047-2054.

DOI：10.1038/leu.2016.101

We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 1878), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n = 1924), (2) tandem auto-allo-HSCT (n = 2004) and (3) allo-HSCT as a second line treatment and beyond (n = 3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.

• 出版日期2016-10
• 单位河南工业大学